4[1]Kramer W, Muller G, Girbig F, et al. Differential interaction of glimepiride and glibenclamide with the βcell sulfonylurea receptor Ⅱ.Photoaffinity labeling of a 65 kDa protein by [3H]glimepiride. Biochim Biophys Acta, 1994, 1191(2):278
5[2]Muller G, Hartz D, Punter J, et al. Differential interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor Ⅰ. Binding characteristics. Biochim Biophys Acta, 1994,1191(2):267
6[3]Massi-Bendetti M, Herz M, Pfeiffer C. The effects of acute exercise on metabolic control in type Ⅱ diabetic patients treated with glimepiride and glibenclamide. Horm Metab Res, 1996,28(9) :451
7[4]Geisen K, Vegh A, Krause E, et al. Cardiovascular effects of conventional sulfony1ureas and glimepiride. Horm Metab Res,1996, 28(9):496
8[5]Bijlstra PJ, Lutterman JA, Rusel FG, et al. Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans. Diabetologia, 1996, 39 (9):1083
9[6]Muller G, Satoh Y, Geisen K. Extra-pancreatic effects of sulfonylurea-a comparison between glimepiride and conventional sulfonylurea. Diabetes Res Clin Pract, 1995(Suppl 28):115
7Jack L,Leahy.Pathogenesis of type 2 diabetes mellitus[J].Arch Med Res,2005,36(3):197.
8James EFR.Martindale:the extra pharmacopoeia 31th ed[M].London:Pharmaceutial Press,1996.87.
9Wolffenbuttel J,Samols E,Muchmore DB,et al.Glimepiride,anew,once-dailysul-fonylurea:adouble-blind,placebo-controlled study of NIDDM patients[J].Diabeties Care,1996,19:1194.
